



NECTAR LIFESCIENCES LIMITED

Regd. Office : Vill. Saidpura, Tehsil Derabassi, Distt. Mohali (Punjab)

Un-audited Financial Results for the Quarter ended 31.12.2011 (Rs. in Lacs)

S No.	PARTICULARS	Quarter ended 31.12.2011	Quarter ended 30.09.2011	Quarter ended 31.12.2010	9 Months Ended 31.12.2011	9 Months Ended 31.12.2010	Year Ended 31.03.2011
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1.	Gross Sales/Income from Operations	41711.79	29937.20	33786.46	93556.36	75932.12	111577.03
	Less : Excise Duty	719.24	919.70	1743.21	2656.77	4191.48	6032.19
	Net Sales / Income from Operations	40992.55	29017.50	32043.25	90899.59	71740.64	105544.84
	Other Operating Income	164.47	238.55	236.82	643.60	445.54	661.44
	Total Operating Income	41157.02	29256.05	32280.07	91543.19	72186.18	106206.28
2.	Expenditure						
	a. (Increase)/decrease in stock in trade	530.37	(444.93)	(803.90)	(84.60)	(2492.08)	(3162.81)
	b. Consumption of Raw Material	28646.10	20577.73	22817.12	62656.31	49044.53	74269.80
	c. Employees Cost	1221.82	1234.39	1090.45	3696.56	2868.53	3716.81
	d. Depreciation	1663.36	1608.57	1164.31	4497.27	3435.50	4609.59
	e. Other Expenditure	3288.82	2163.85	2341.95	7593.74	6011.18	8694.38
	Total Expenditure	35350.47	25139.61	26609.93	78359.28	58867.66	88127.77
3.	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	5806.55	4116.44	5670.14	13183.91	13318.52	18078.51
4.	Other Income	412.18	450.57	12.53	862.83	18.24	1345.58
5.	Profit before Interest & Exceptional Items (3+4)	6218.73	4567.01	5682.67	14046.74	13336.76	19424.09
6.	Interest	2542.82	2107.77	1567.30	6610.95	4185.67	7408.40
7.	Profit after Interest but before Exceptional Items (5-6)	3675.91	2459.24	4115.37	7435.79	9151.09	12015.69
8.	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9.	Profit from ordinary activities before tax (7+8)	3675.91	2459.24	4115.37	7435.79	9151.09	12015.69
10.	Tax Expenses	436.94	328.94	1093.85	944.54	2146.37	1734.68
11.	Net Profit from ordinary activities after tax (9-10)	3238.97	2130.30	3021.52	6491.25	7004.72	10281.01
12.	Extraordinary Item (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00
13.	Net Profit for the period (11-12)	3238.97	2130.30	3021.52	6491.25	7004.72	10281.01
14.	Paid up Equity Share Capital (Face Value per share : Re.1/-)	2242.61	2242.61	2242.61	2242.61	2242.61	2242.61
15.	Reserves excluding Revaluation Reserves						69875.75
16.	Earnings per Share (EPS)						
	Basic EPS before Extraordinary items	1.44	0.95	1.35	2.89	3.12	4.63
	Diluted EPS before Extraordinary items	1.44	0.95	1.07	2.89	2.49	4.63
	Basic EPS after Extraordinary items	1.44	0.95	1.35	2.89	3.12	4.63
	Diluted EPS after Extraordinary items	1.44	0.95	1.07	2.89	2.49	4.63
17.	Public Shareholding						
	- Number of Shares	124856970	124896970	125246970	124856970	125246970	124969970
	- Percentage of Shareholding	55.67	55.69	55.85	55.67	55.85	55.73
18.	Promoters & Promoter Group Shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	0	0	0	0	0	0
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00	0.00	0.00
	- Percentage of Shares (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00	0.00	0.00
	b) Non-encumbered						
	- Number of Shares	99404000	99364000	99014000	99404000	99014000	99291000
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the company)	44.33	44.31	44.15	44.33	44.15	44.27

Notes : 1. The above financial results were reviewed by Audit Committee on 10.02.2012 and approved by the Board in its meeting held on even date i.e. 10.02.2012 and further limited reviewed by the Statutory Auditors of the Company.

2. The company is exclusively in the pharmaceutical business segment.
3. The above financial results are on stand alone basis.
4. As required by the Accounting Standard -11 on "The effect of change in foreign exchange rates" , there is a notional loss on foreign currency loans during the quarter, which would be recognised, if any, at the end of accounting year.
5. Status of Complaints:

a) Pending at the beginning of Quarter - Nil	b) Received During the Quarter - 11
c) Disposed Off During the Quarter - 11	d) Pending at the end of Quarter - Nil

**By Order of the Board of Directors
of Nectar Lifesciences Limited**

Sd/-

(Sanjiv Goyal)

Chairman and Managing Director

Dated : 10.02.2012

Place : Chandigarh